{
  "snapshot_date": "2026-04-26",
  "source": "synthetic_ir_sec_edgar",
  "items": [
    {
      "id": "IR-MDGL-SYN-2026-04-26-01",
      "type": "8-K",
      "sponsor": "Madrigal",
      "headline": "Synthetic Q1 update: real-world synthetic MASH cohort interim data (synthetic)",
      "drugs": ["resmetirom"],
      "date": "2026-04-26"
    },
    {
      "id": "IR-AKRO-SYN-2026-04-26-02",
      "type": "PR",
      "sponsor": "Akero",
      "headline": "Akero announces synthetic 96-week histology readout planning (synthetic)",
      "drugs": ["efruxifermin"],
      "date": "2026-04-26"
    },
    {
      "id": "IR-ETNB-SYN-2026-04-26-03",
      "type": "8-K",
      "sponsor": "89bio",
      "headline": "89bio synthetic ENLIGHTEN-Synth enrollment milestone (synthetic)",
      "drugs": ["pegozafermin"],
      "date": "2026-04-26"
    },
    {
      "id": "IR-ALT-SYN-2026-04-26-04",
      "type": "PR",
      "sponsor": "Altimmune",
      "headline": "Altimmune synthetic IMPACT-Synth topline summary released (synthetic)",
      "drugs": ["pemvidutide"],
      "date": "2026-04-26"
    },
    {
      "id": "IR-IVA-SYN-2026-04-26-05",
      "type": "PR",
      "sponsor": "Inventiva",
      "headline": "Inventiva synthetic NATIV3-Synth DSMB safety review reaffirms continuation (synthetic)",
      "drugs": ["lanifibranor"],
      "date": "2026-04-26"
    }
  ]
}